+1 to CarlaRPh_TPA. Especially the point about "RaviCardio perspective but I think this ..." — I have seen the same in my own experience with USP <797> 2023 revision.
Want to share my personal experience related to USP <797> 2023 revision impact since I think it might help others in a similar situation.
I started my GLP-1 journey in October 2024 at 267 lbs with prediabetes and hypertension. My endocrinologist prescribed semaglutide 0.25mg to start.
Now, 18 months later: I am down 87 lbs, my labs have normalized, and I am off 2 of my 3 medications. The USP <797> 2023 aspect specifically was something that made a big difference in my journey.
This community helped me every step of the way.
sophie_paris — that is really helpful context on USP <797> 2023 revision. Follow-up question: did you experience any side effects during this phase?
I am in a similar situation (about to start) and trying to set realistic expectations.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsTo answer DebRD_ATL's question specifically:
From a clinical standpoint, USP <797> 2023 revision impact is something I discuss with patients regularly.
The short answer: discuss this specific situation with your prescribing provider.
The longer answer involves weighing the risk-benefit ratio for your individual situation, which I am happy to elaborate on if helpful.
Saving this for reference. Quality thread.